1,8 Cineole and Ellagic acid inhibit hepatocarcinogenesis via upregulation of MiR-122 and suppression of TGF-β1, FSCN1, Vimentin, VEGF, and MMP-9
Authors:
Open Access
- 26 January 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (1) , e0258998
Abstract
Hepatocellular carcinoma (HCC) is one of the most burdened tumors worldwide, with a complex and multifactorial pathogenesis. Current treatment approaches involve different molecular targets. Phytochemicals have shown considerable promise in the prevention and treatment of HCC. We investigated the efficacy of two natural components, 1,8 cineole (Cin) and ellagic acid (EA), against diethylnitrosamine/2-acetylaminofluorene (DEN/2-AAF) induced HCC in rats. DEN/2-AAF showed deterioration of hepatic cells with an impaired functional capacity of the liver. In addition, the levels of tumor markers including alpha-fetoprotein, arginase-1, alpha-L-fucosidase, and ferritin were significantly increased, whereas the hepatic miR-122 level was significantly decreased in induced-HCC rats. Interestingly, treatment with Cin (100mg/kg) and EA (60mg/kg) powerfully restored these biochemical alterations. Moreover, Cin and EA treatment exhibited significant downregulation in transforming growth factor beta-1 (TGF-β1), Fascin-1 (FSCN1), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and epithelial-mesenchymal transition (EMT) key marker, vimentin, along with a restoration of histopathological findings compared to HCC group. Such effects were comparable to Doxorubicin (DOX) (2mg/kg); however, a little additive effect was evident through combining these phytochemicals with DOX. Altogether, this study highlighted 1,8 cineole and ellagic acid for the first time as promising phytochemicals for the treatment of hepatocarcinogenesis via regulating multiple targets.Keywords
Funding Information
- National Research Centre (11010330)
This publication has 59 references indexed in Scilit:
- Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular CarcinomaNanomaterials, 2016
- Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and ratsScientific Reports, 2016
- MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor MetabolismPLOS ONE, 2016
- VEGFR-1 Activation-Induced MMP-9-Dependent Invasion in Hepatocellular CarcinomaFuture Oncology, 2015
- Gastroprotective Mechanisms of the Monoterpene 1,8-Cineole (Eucalyptol)PLOS ONE, 2015
- Diagnostic value of alpha-l-fucosidase for hepatocellular carcinoma: a meta-analysisTumor Biology, 2014
- Histopathologic features of hepatocellular carcinomaClinical Liver Disease, 2012
- Arginase-1, HepPar-1, and Glypican-3 Are the Most Effective Panel of Markers in Distinguishing Hepatocellular Carcinoma From Metastatic Tumor on Fine-Needle Aspiration SpecimensAmerican Journal of Clinical Pathology, 2012
- Reference Genes for Real-Time PCR Quantification of MicroRNAs and Messenger RNAs in Rat Models of HepatotoxicityPLOS ONE, 2012
- Liver‐specific overexpression of matrix metalloproteinase 9 (MMP‐9) in transgenic mice accelerates development of hepatocellular carcinomaMolecular Carcinogenesis, 2011